Maltofer, drops 50 mg/ml 30 ml

Maltofer contains iron in the form of a polymaltose complex of iron (III) hydroxide. < br>

This macromolecular complex is stable and does not release iron in the form of free ions in the gastrointestinal tract. < br>

The structure of drug Maltofer® is similar to the natural compound of iron – ferritin. < br>

Due to this similarity, iron (III) is transported from the intestine into the blood by active transport. < br>

The absorbed iron is bound to ferritin and stored in the body, mainly in the liver. It is then incorporated into hemoglobin in the bone marrow. < br>

The iron in the polymaltose complex of iron (III) hydroxide does not have pro-oxidant properties, unlike simple iron salts. < br>

There is a correlation between the severity of iron deficiency and the level of iron absorption (the greater the severity of iron deficiency, the better the absorption).

The most active absorption occurs in the duodenum and small intestine.

The drug Maltofer® does not cause staining of tooth enamel.

< br>

Indications

Appetite disturbance, Dizziness, Appetite disturbance, Pale skin, Weakness and fatigue, Low performance, Prevention of iron deficiency, Bleeding, Tinnitus, Anemia

Latent iron deficiency and clinically expressed iron deficiency (iron deficiency anemia);

Prevention of iron deficiency in women during pregnancy, breastfeeding, childbirth, children, including adolescents.In children, including adolescents, in adults (e.g. vegetarians and the elderly).

Composition

Active ingredient:

iron in the form of polymaltose complex of iron (III)hydroxide 50 mg;

Auxiliary substances:

Sodium methyl parahydroxybenzoate;

Sodium propyl parahydroxybenzoate;

Sodium hydroxide;

Purified water;

sugarose;

Cream flavoring;

How to take, the dosage

Ingestion.

Take with or immediately after meals.

The daily dose of the drug depends on the degree of iron deficiency.

The duration of treatment of clinically expressed iron deficiency (iron deficiency anemia) is 3-5 months, until normalization of hemoglobin levels.

Thereafter, the drug should be continued in the dosage for the treatment of latent iron deficiency for several more months, and for pregnant women, at least until delivery to restore iron reserves.

The duration of treatment of latent iron deficiency is 1-2 months.

In cases of clinically pronounced iron deficiency, normalization of hemoglobin levels and replenishment of iron reserves does not occur until 2-3 months after treatment begins.

Interaction

Interaction with other drugs was not detected.

.

Special Instructions

When prescribing the drug to patients with diabetes it is necessary to take into account that 1 ml of drops for oral administration contains 0.01 units, 1 ml of syrup – 0.04 units, 1 chewable tablet – 0.04 units.

Maltofer® does not cause staining of teeth enamel.

Contraindications

• iron overload (e.g. hemosiderosis and hemochromatosis);
• inferior iron utilization (lead anemia, sideroachrestic anemia);
• non-iron deficiency anemia (hemolytic or megaloblastic, caused by vitamin B12 deficiency).

.

Side effects

Gastrointestinal disorders: feeling of fullness, pressure in the epigastric region, nausea, constipation or diarrhea; dark staining of stools is possible due to excretion of unabsorbed iron, which is of no clinical significance.

.

Overdose

To date, no intoxication or signs of iron overload have been reported in cases of drug overdose.

Pregnancy use

In controlled studies in pregnant women after the first trimester of pregnancy no undesirable effects of the drug on the mother or fetus have been observed.

There are no data on undesirable effects of the drug on the fetus in the first trimester of pregnancy.

.